Treating non-responders: pitfalls and implications for cancer immunotherapy trial design

BACKGROUND: Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment. Treating non-responders, we hypothesize, would in part drive non-proportional haza...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhenzhen, Park, Yongsoek, Liu, Ke, Zhu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071722/
https://www.ncbi.nlm.nih.gov/pubmed/32171307
http://dx.doi.org/10.1186/s13045-020-0847-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071722/
https://www.ncbi.nlm.nih.gov/pubmed/32171307
http://dx.doi.org/10.1186/s13045-020-0847-x

Ejemplares similares